Drug Discovery Initiative (DDI)
A major bottleneck in the development of effective drugs is the identification of new candidate compounds to be clinically evaluated. BIO5 is positioned to provide biopharmaceutical companies in Arizona and beyond with innovative drug candidates. BIO5 is capitalizing on its highly innovative basic biology and genetics programs to provide drug targets for potential disease treatments. BIO5's medicinal chemistry faculty combines academic and pharmaceutical industry expertise in drug discovery. They work in close association with a strong cancer center faculty that have an excellent record of drug development.
BIO5 will work closely with C-Path (Critical Path to Accelerate Therapies), a tri-agency partnership among the UA, the FDA and Stanford Research Institute. C-Path will investigate safer and more efficient mechanisms for getting new drugs to market.